Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285:2370-2375.
DeWilde S, Carey IM, Emmas C, et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care Heart. 2006;92:1064-1107.
Perera KS, Vanassche T, Bosch J, et al. Global survey of the frequency of atrial fibrillation-associated stroke: embolic stroke of undetermined source global registry. Stroke. 2016;47:2197-2202.
Kirchoff P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962.
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. Circulation. 2014;130:2071-2104.
Daniels PR. Peri-procedural management of patients taking oral anticoagulants. BMJ. 2015;351:h2391.
Larsen TB, Skjøth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016:353:i3189.
Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482.
Boriani G, Proietti M. Atrial fibrillation prevention: an appraisal of current evidence. Heart. 2018;104:882-887.
Kalantarian S, Stern TA, Mansour M, et al. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann Intern Med. 2016;158:338-346.
Senoo K, Lane Deirdre, Lip GYH. Stroke and bleeding risk in atrial fibrillation. Korean Circ J. 2014;44:281-290.
Amin A. Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies. Clin Intervent Aging. 2013;8:75-84.
Wyse DG, AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833.
Bond R, Olshansky B, Kirchhof P. Recent advances in rhythm control for atrial fibrillation. F1000Res. 2017;6:1796.
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383:955-962.
Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017;14:627-628.
Andersson T, Magnuson A, Bryngelsson I-L, et al. Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: A nationwide cohort study of 9519 patients. Int J Cardiol. 2014;177:91-99.
Chamberlain AM, Alonso A, Gersh BJ, et al. Multimorbidity and the risk of hospitalization and death in atrial fibrillation: a population-based study. Am Heart J. 2017;185:74-84.
Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14:e275‐e444.
Yoon M, Yang PS, Jang E, et al. Dynamic changes of CHA2DS2-VASc score and the risk of ischaemic stroke in Asian patients with atrial fibrillation: a nationwide cohort study. Thromb Haemost. 2018;118:1296-1304.
Hijazi Z, Oldgren J, Siegbahn A, et al. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J. 2013;34:1475-1480.
Kuhlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol cr/xl to maintain sinus rhythm after conversion from persistent atrial fibrillation. J Am Coll Cardiol. 2000;36:139-146.
Beatch G, Mangal B. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial. BMC Cardiovasc Disords. 2016;16:133.
Kiliszek M, Opolski G, Włodarczyk P, et al. Cardioversion of atrial fibrillation (RHYTHM-AF) international registry in Poland. Cardiol J. 2014;21:484-491.
Lo LW, Lin YJ, Chang SL, et al. Predictors and characteristics of multiple (more than 2) catheter ablation procedures for atrial fibrillation. J Cardiovasc Electrophysiol. 2015;26:1048-1056.
Mansour M, Karst E, Heist EK, et al. The impact of first procedure success rate on the economics of atrial fibrillation ablation. JACC Clin Electrophysiol. 2017;3:129-138.
Anselmino M, Matta M, Bunch T, et al. Conduction recovery following catheter ablation in patients with recurrent atrial fibrillation and heart failure. Int J Cardiol. 2017;240:240-245.
Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA. 2014;311:692-700.
Mujovic N, Marinkovic M, Lenarczyk R, et al. Catheter ablation of atrial fibrillation: an overview for clinicians. Adv Ther. 2017;34:1897-1917.
Aliot E, Botto GL, Crijns HJ, et al. Quality of life in patients with atrial fibrillation: how to assess it and how to improve it. Europace. 2014;16:787-796.
Global Burden of Disease Collaborative Network. Institute for Health Metrics and Evaluation (IHME). 2017. http://ghdx.healthdata.org/gbd-results-tool. Accessed September 12, 18.
Pathak RV, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation. J A m C oll C ardiol. 2014;64:2222-2231.
de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation. J A m C oll C ardiol. 2010;55:725-731.
Duytschaever M, Demolder A, Philips T, et al. PulmOnary vein isolation With vs without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. Eur Heart J. 2018;39:1429-1437.
Packer DL, Lee KL, Mark DB, et al. Catheter ABlation vs ANtiarrhythmic drug therapy in Atrial fibrillation: (CABANA) trial. Scientific Sessions. Annual Meeting of the European Society of Cardiology; August 2018; Munich, Germany.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Raffaele De Caterina, MD, PhD

Professor of Cardiology
Director
University Cardiology Division
University Hospital
Chieti, Italy

Disclosures

Disclosure: Raffaele De Caterina, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Roche
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation
Received grants for clinical research from: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.

Mattias Duytschaever, MD, PhD

Professor of Medicine
St. Jan Hospital Bruges
Bruges, Belgium

Disclosures

Disclosure: Mattias Duyschaever, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Biosense Webster, Inc.
Served as a speaker or a member of a speakers bureau for: Biosense Webster, Inc.

Gerhard Hindricks, MD

Professor of Medicine
University of Leipzig
Heart Center Leipzig
Leipzig, Germany

Disclosures

Disclosure: Gerhard Hindricks, MD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Abbott Laboratories; Boston Scientific

Gregory Y.H. Lip, MD

Professor
Institute of Cardiovascular Sciences
University of Birmingham
Birmingham, United Kingdom

Disclosures

Disclosure: Gregory Y. H. Lip, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; Medtronic, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Verseon
Served as a speaker or a member of a speakers bureau for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Medtronic, Inc.; Pfizer Inc.

Editor

Robert McCarthy, PhD

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Robert McCarthy, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

CPD

Navigating the Continuum of Care in Cardiac Arrhythmia Management

Authors: Raffaele De Caterina, MD, PhD; Mattias Duytschaever, MD, PhD; Gerhard Hindricks, MD; Gregory Y. H. Lip, MD
CPD Released: 10/25/2018
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 10/25/2019, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for an international audience of non-US cardiologists, primary care physicians, and neurologists.

The goal of this activity is to increase physician awareness of nonpharmacologic treatments for cardiac arrhythmias.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Recognition and diagnosis of atrial fibrillation (AF) and its potential clinical sequelae
- Clinical guidelines for AF ablation
- Results of the latest clinical trials on AF ablation
Have greater competence related to
- The role that ablation should play in the management of patients with AF

Disclosures

Faculty

Raffaele De Caterina, MD, PhD

Professor of Cardiology
Director
University Cardiology Division
University Hospital
Chieti, Italy

Disclosures

Disclosure: Raffaele De Caterina, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Roche
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation
Received grants for clinical research from: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.

Mattias Duytschaever, MD, PhD

Professor of Medicine
St. Jan Hospital Bruges
Bruges, Belgium

Disclosures

Disclosure: Mattias Duyschaever, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Biosense Webster, Inc.
Served as a speaker or a member of a speakers bureau for: Biosense Webster, Inc.

Gerhard Hindricks, MD

Professor of Medicine
University of Leipzig
Heart Center Leipzig
Leipzig, Germany

Disclosures

Disclosure: Gerhard Hindricks, MD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Abbott Laboratories; Boston Scientific

Gregory Y.H. Lip, MD

Professor
Institute of Cardiovascular Sciences
University of Birmingham
Birmingham, United Kingdom

Disclosures

Disclosure: Gregory Y. H. Lip, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; Medtronic, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Verseon
Served as a speaker or a member of a speakers bureau for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Medtronic, Inc.; Pfizer Inc.

Editor

Robert McCarthy, PhD

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Robert McCarthy, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Navigating the Continuum of Care in Cardiac Arrhythmia Management

Authors: Raffaele De Caterina, MD, PhD; Mattias Duytschaever, MD, PhD; Gerhard Hindricks, MD; Gregory Y. H. Lip, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 10/25/2018

Valid for credit through: 10/25/2019, 11:59 PM EST

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

Download Now

CPD Information

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the European Medicines Agency for use in Europe and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Faculty

Raffaele De Caterina, MD, PhD

Mattias Duytschaever, MD, PhD

Gerhard Hindricks, MD

Gregory Y.H. Lip, MD

Editor

Robert McCarthy, PhD

Content Reviewer

Nafeez Zawahir, MD

CPD

Navigating the Continuum of Care in Cardiac Arrhythmia Management

Target Audience and Goal Statement

Disclosures

Faculty

Raffaele De Caterina, MD, PhD

Mattias Duytschaever, MD, PhD

Gerhard Hindricks, MD

Gregory Y.H. Lip, MD

Editor

Robert McCarthy, PhD

Content Reviewer

Nafeez Zawahir, MD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Navigating the Continuum of Care in Cardiac Arrhythmia Management